Drug Trial Radar · NCT00909857
Effect on Primary Dysmenorrhea
Last checked: Nov 20, 2026Latest source record: Aug 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
507
Actual
Start
Apr 2009
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- May 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 14 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the potential benefits of a new oral contraceptive (SH T00658ID) on alleviating complaints of dysmenorrhea associated with oral contraceptive use.
Conditions
- Primary Dysmenorrhea
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)Drug
Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
Ethinyl estradiol, Levonorgestrel (Miranova)Drug
Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
Placebo Match to SH T00658IDDrug
Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
Placebo Match to SH D593BDrug
Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic PainTime frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Locations
41 sites in 6 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
San Diego, California
Site not named
Hialeah, Florida
Site not named
Leesburg, Florida
Site not named
Sandy Springs, Georgia
Site not named
Idaho Falls, Idaho
Site not named
Winston-Salem, North Carolina
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
La Crosse, Wisconsin
Site not named
Langley, British Columbia, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Pointe-Claire, Quebec, Canada
Site not named
Ste-Foy, Quebec, Canada
Site not named
Regina, Saskatchewan, Canada
Site not named
Santiago, Chile
Site not named
Talcahuano, Chile
Site not named
Temuco, Chile
Site not named
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Site not named
Hamburg, Free and Hanseatic City of Hamburg, Germany
Site not named
Cologne, North Rhine-Westphalia, Germany
Site not named
Essen, North Rhine-Westphalia, Germany
Site not named
Leipzig, Saxony, Germany
Site not named
Bernburg, Saxony-Anhalt, Germany
Site not named
Magdeburg, Saxony-Anhalt, Germany
Site not named
Bologna, Italy
Site not named
Brescia, Italy
Site not named
Milan, Italy
Site not named
Modena, Italy
Site not named
Perugia, Italy
Site not named
Roma, Italy
Site not named
Siena, Italy
Site not named
Torino, Italy
Site not named
Udine, Italy
Site not named
Francavilla Fontana, Brindisi, Italy
Site not named
Cebu, Philippines
Site not named
Cebu City, Philippines
Site not named
Davao City, Philippines
Site not named
Metro Manila, Philippines
Site not named
Metro Manila, Philippines
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.